GlassScriptPhysician profile
Ilyes Benchaala
NPI 1346578127
$15,418.07
in general payments reported to CMS, 2019-2025
37 companies · $4,233 in 2025
The $4,233 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,136 · 2020: $2,269 · 2021: $1,131 · 2022: $1,316 · 2023: $2,064 · 2024: $2,269 · 2025: $4,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,274 · Travel and Lodging: $791 · Education: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,274.39 |
| Travel and Lodging | $790.63 |
| Education | $501.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,694.88 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $2,689.51 | 2019-2025 | |
| Abbvie INC. | $2,060.62 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,594.13 | 2019-2025 | Tremfya, Stelara, Erleada |
| Glaxosmithkline, LLC. | $727.67 | 2019-2025 | Benlysta |
| Amgen INC. | $666.33 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Pfizer INC. | $581.54 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $373.97 | 2023-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $324.58 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.31 | 2019-2025 | Ofev, Cyltezo, Spevigo |
| Astrazeneca Pharmaceuticals LP | $308.84 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $304.09 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $272.62 | 2023-2025 | Lupkynis |
| Lilly USA, LLC | $219.13 | 2019-2023 | Taltz |
| Regeneron Healthcare Solutions, INC. | $213.52 | 2019 |
Show all 36 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilyes Benchaala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.